close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ellipses Pharma

News headline image
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026
From Ellipses Pharma
Via Business Wire
News headline image
Ellipses Pharma Announces Intent to Accelerate Clinical Programme Following ‘Encouraging’ Data on Next Generation Selective RET Inhibitor
From Ellipses Pharma
Via Business Wire
News headline image
Ellipses Pharma: Expansion of Scientific Affairs Group
From Ellipses Pharma
Via Business Wire
News headline image
Ellipses Pharma: EP0042 Receives Orphan Drug Designation from the US Food and Drug Administration
From Ellipses Pharma
Via Business Wire
News headline image
Ellipses Pharma Announces FDA Approval of IND Application for EP0042 for Patients With Acute Myeloid Leukaemia
From Ellipses Pharma
Via Business Wire
News headline image
Ellipses Announces First Patient Dosed with EP0031, a Next Generation Selective RET Inhibitor
From Ellipses Pharma
Via Business Wire
News headline image
Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With Advanced RET-altered Malignancies
From Ellipses Pharma
Via Business Wire
News headline image
Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein
From Ellipses Pharma
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today